These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 9322657

  • 1. Hormone replacement therapy and the risk of breast lesions that predispose to cancer.
    Cahn MD, Tran T, Theur CP, Butler JA.
    Am Surg; 1997 Oct; 63(10):858-60. PubMed ID: 9322657
    [Abstract] [Full Text] [Related]

  • 2. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):563-71. PubMed ID: 18398105
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M, Koera K, Nagata H, Nakano H.
    J Obstet Gynaecol Res; 2004 Aug 16; 30(4):297-302. PubMed ID: 15238106
    [Abstract] [Full Text] [Related]

  • 5. Risk of breast cancer in women with benign breast disease.
    Hutchinson WB, Thomas DB, Hamlin WB, Roth GJ, Peterson AV, Williams B.
    J Natl Cancer Inst; 1980 Jul 16; 65(1):13-20. PubMed ID: 6930509
    [Abstract] [Full Text] [Related]

  • 6. Cancer surveillance during HRT.
    Palacios S.
    Int J Fertil Menopausal Stud; 1994 Jul 16; 39 Suppl 2():93-8. PubMed ID: 7874192
    [Abstract] [Full Text] [Related]

  • 7. Multiplicity of benign breast lesions is a risk factor for progression to breast cancer.
    Worsham MJ, Raju U, Lu M, Kapke A, Cheng J, Wolman SR.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5474-9. PubMed ID: 17875777
    [Abstract] [Full Text] [Related]

  • 8. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.
    Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ.
    Cancer; 2006 Sep 15; 107(6):1240-7. PubMed ID: 16902983
    [Abstract] [Full Text] [Related]

  • 9. Benign breast disease and the risk of breast cancer.
    Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW.
    N Engl J Med; 2005 Jul 21; 353(3):229-37. PubMed ID: 16034008
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study.
    Espié M, Mares P, de Reilhac P, Chevallier T, Daurès JP.
    Gynecol Endocrinol; 2006 Aug 21; 22(8):423-31. PubMed ID: 17012103
    [Abstract] [Full Text] [Related]

  • 13. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
    Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD, Trevisan M, Vito D, Modali R, Lehman TA, Seddon M, Edge SB, Marian C, Muti P, Freudenheim JL.
    Cancer Epidemiol Biomarkers Prev; 2008 May 21; 17(5):1082-7. PubMed ID: 18483329
    [Abstract] [Full Text] [Related]

  • 14. Controversies over hormone replacement therapy. HRT as a risk factor of breast cancer in postmenopausal women.
    Licznerska BE, Baer-Dubowska W.
    Acta Pol Pharm; 2005 May 21; 62(3):241-7. PubMed ID: 16193819
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk factors for breast cancer in women with proliferative breast disease.
    Dupont WD, Page DL.
    N Engl J Med; 1985 Jan 17; 312(3):146-51. PubMed ID: 3965932
    [Abstract] [Full Text] [Related]

  • 18. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES.
    Ann Surg Oncol; 2007 Feb 17; 14(2):695-703. PubMed ID: 17103262
    [Abstract] [Full Text] [Related]

  • 19. [Hormone replacement therapy and breast cancer].
    Dobashi K.
    Gan To Kagaku Ryoho; 1999 Jun 17; 26(7):871-6. PubMed ID: 10396312
    [Abstract] [Full Text] [Related]

  • 20. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
    Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ.
    Cancer; 2003 Dec 15; 98(12):2539-46. PubMed ID: 14669271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.